Characteristics of adverse drug reactions and risk management strategies for methylprednisolone sodium succinate in the treatment of idiopathic sudden sensorineural hearing loss: a clinical study of 1026 patients.

Ting Wu, Yu Tang, Sinan Yan, Jie Meng, Shuangba He, Wei Meng

Abstract read

In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Network-Based Identification ofCurrent pharmaceutical design · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ting Wu *Department of Otorhinolaryngology Head and Neck Surgery, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, China.

Yu Tang *Department of Otorhinolaryngology Head and Neck Surgery, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, China.

Sinan YanDepartment of Otorhinolaryngology Head and Neck Surgery, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, China.

Jie MengDepartment of Otorhinolaryngology Head and Neck Surgery, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, China.

Shuangba HeDepartment of Otorhinolaryngology Head and Neck Surgery, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, China.

Wei MengDepartment of Otorhinolaryngology Head and Neck Surgery, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To systematically analyze the patterns, risk factors, and clinical management strategies of adverse drug reactions (ADRs) associated with methylprednisolone sodium succinate in the treatment of idiopathic sudden sensorineural hearing loss (ISSNHL). Methods: A retrospective study was conducted on 1026 ISSNHL patients treated with methylprednisolone sodium succinate at Nanjing Tongren Hospital from January 2020 to December 2024. The incidence, types, severity, and outcomes of ADRs were recorded. Multivariate logistic regression was used to identify risk factors, and evidence-based intervention recommendations were proposed. Results: The overall ADRs incidence was 17.2% (177/1026), with gastrointestinal reactions (43.5%), elevated blood glucose (29.9%), and neuropsychiatric symptoms (18.1%) being the most common. Advanced age (≥60 years, OR = 2.24) and diabetes (OR = 3.15) were independent risk factors for ADRs (both Conclusion: The risk of ADRs from methylprednisolone sodium succinate is closely related to patients' underlying conditions and treatment regimens. A stratified warning system and optimized individualized treatment strategies are necessary.

Indexed as

ADRsclinical managementevidence-based medicineISSNHLmethylprednisolone sodium succinate

Identifiers

PMID40568206

DOI10.3389/fmed.2025.1589531

PMCPMC12187723

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.